Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin

Nature Medicine

Volumn 19, Issue 12, 2013, Pages 1649-1654

  Fullerton, Morgan D ^a   Galic, Sandra ^b   Marcinko, Katarina ^a   Sikkema, Sarah ^a   Pulinilkunnil, Thomas ^c   Chen, Zhi Ping ^b   O'Neill, Hayley M ^a,b,d   Ford, Rebecca J ^a   Palanivel, Rengasamy ^a   O'Brien, Matthew ^b,d   Hardie, D Grahame ^e   MacAulay, S Lance ^f   Schertzer, Jonathan D ^a   Dyck, Jason R B ^c   Van Denderen, Bryce J ^b   Kemp, Bruce E ^b,d   Steinberg, Gregory R ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF DUNDEE   (United Kingdom)

^f CSIRO   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACC1 PROTEIN; ACC2 PROTEIN; ALANINE; MEMBRANE PROTEIN; METFORMIN; SERINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISORDERS OF CARBOHYDRATE METABOLISM; FATTY ACID OXIDATION; GENE MUTATION; HOMEOSTASIS; INSULIN RESISTANCE; LIPID HOMEOSTASIS; LIPOGENESIS; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WILD TYPE;

MUS;

EID: 84889887123     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3372     Document Type: Article

References (45)

1. Kahn, B.B., Alquier, T., Carling, D. & Hardie, D.G. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 1, 15-25 (2005). (Pubitemid 43960587)
2. Long, Y.C. & Zierath, J.R. AMP-activated protein kinase signaling in metabolic regulation. J. Clin. Invest. 116, 1776-1783 (2006). (Pubitemid 44033297)
3. Carlson, C.A. & Kim, K.H. Regulation of hepatic acetyl coenzyme A carboxylase by phosphorylation and dephosphorylation. J. Biol. Chem. 248, 378-380 (1973).
4. Carling, D., Zammit, V.A. & Hardie, D.G. A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis. FEBS Lett. 223, 217-222 (1987).
5. Wakil, S.J., Stoops, J.K. & Joshi, V.C. Fatty acid synthesis and its regulation. Annu. Rev. Biochem. 52, 537-579 (1983). (Pubitemid 13030689)
6. McGarry, J.D., Leatherman, G.F. & Foster, D.W. Carnitine palmitoyltransferase I. The site of inhibition of hepatic fatty acid oxidation by malonyl-CoA. J. Biol. Chem. 253, 4128-4136 (1978). (Pubitemid 8380630)
7. Harada, N. et al. Hepatic de novo lipogenesis is present in liver-specific ACC1-deficient mice. Mol. Cell Biol. 27, 1881-1888 (2007).
8. Mao, J. et al. Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis. Proc. Natl. Acad. Sci. USA 103, 8552-8557 (2006). (Pubitemid 43838493)
9. Abu-Elheiga, L., Matzuk, M.M., Abo-Hashema, K.A. & Wakil, S.J. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science 291, 2613-2616 (2001). (Pubitemid 32249687)
10. Hoehn, K.L. et al. Acute or chronic upregulation of mitochondrial fatty acid oxidation has no net effect on whole-body energy expenditure or adiposity. Cell Metab. 11, 70-76 (2010).
11. Olson, D.P., Pulinilkunnil, T., Cline, G.W., Shulman, G.I. & Lowell, B.B. Gene knockout of Acc2 has little effect on body weight, fat mass, or food intake. Proc. Natl. Acad. Sci. USA 107, 7598-7603 (2010).
12. Choi, C.S. et al. Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity. Proc. Natl. Acad. Sci. USA 104, 16480-16485 (2007).
13. Munday, M.R., Campbell, D.G., Carling, D. & Hardie, D.G. Identification by amino acid sequencing of three major regulatory phosphorylation sites on rat acetyl-CoA carboxylase. Eur. J. Biochem. 175, 331-338 (1988).
14. Savage, D.B. et al. Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J. Clin. Invest. 116, 817-824 (2006). (Pubitemid 43326891)
15. Erion, D.M. & Shulman, G.I. Diacylglycerol-mediated insulin resistance. Nat. Med. 16, 400-402 (2010).
16. Samuel, V.T. et al. Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J. Clin. Invest. 117, 739-745 (2007). (Pubitemid 46348532)
17. Yu, C. et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J. Biol. Chem. 277, 50230-50236 (2002). (Pubitemid 36042170)
18. Chibalin, A.V. et al. Downregulation of diacylglycerol kinase contributes to hyperglycemia-induced insulin resistance. Cell 132, 375-386 (2008). (Pubitemid 351191998)
19. Hirosumi, J. et al. A central role for JNK in obesity and insulin resistance. Nature 420, 333-336 (2002). (Pubitemid 35398190)
20. O'Neill, H.M. et al. AMP-activated protein kinase (AMPK) 12 muscle null mice reveal an essential role for AMPK in maintaining mitochondrial content and glucose uptake during exercise. Proc. Natl. Acad. Sci. USA 108, 16092-16097 (2011).
21. Foretz, M. et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J. Clin. Invest. 120, 2355-2369 (2010).
22. Viollet, B. et al. Cellular and molecular mechanisms of metformin: an overview. Clin. Sci. (Lond.) 122, 253-270 (2012).
23. Zhou, G. et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167-1174 (2001). (Pubitemid 32995375)
24. Miller, R.A. et al. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 494, 256-260 (2013).
25. Musso, G., Cassader, M., Rosina, F. & Gambino, R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 55, 885-904 (2012).
26. Bailey, C.J. & Mynett, K.J. Insulin requirement for the antihyperglycaemic effect of metformin. Br. J. Pharmacol. 111, 793-796 (1994). (Pubitemid 24151666)
27. Bailey, C.J. & Turner, R.C. Metformin. N. Engl. J. Med. 334, 574-579 (1996). (Pubitemid 126537875)
28. Gómez-Sámano, M.Á. et al. Metformin and improvement of the hepatic insulin resistance index independent of anthropometric changes. Endocr. Pract. 18, 8-16 (2012).
29. Natali, A. & Ferrannini, E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 49, 434-441 (2006). (Pubitemid 43277865)
30. Cool, B. et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab. 3, 403-416 (2006). (Pubitemid 43811782)
31. Li, Y. et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab. 13, 376-388 (2011).
32. Foretz, M., Carling, D., Guichard, C., Ferre, P. & Foufelle, F. AMP-activated protein kinase inhibits the glucose-activated expression of fatty acid synthase gene in rat hepatocytes. J. Biol. Chem. 273, 14767-14771 (1998). (Pubitemid 28272762)
33. Lalau, J.D., Lemaire-Hurtel, A.S. & Lacroix, C. Establishment of a database of metformin plasma concentrations and erythrocyte levels in normal and emergency situations. Clin. Drug Investig. 31, 435-438 (2011).
34. Owen, M.R., Doran, E. & Halestrap, A.P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 348, 607-614 (2000). (Pubitemid 30410251)
35. Wilcock, C. & Bailey, C.J. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 24, 49-57 (1994). (Pubitemid 24058005)
36. Clark, J.M., Brancati, F.L. & Diehl, A.M. Nonalcoholic fatty liver disease. Gastroenterology 122, 1649-1657 (2002). (Pubitemid 34533559)
37. He, L. et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 137, 635-646 (2009).
38. Turban, S. et al. Defining the contribution of AMP-activated protein kinase (AMPK) and protein kinase C (PKC) in regulation of glucose uptake by metformin in skeletal muscle cells. J. Biol. Chem. 287, 20088-20099 (2012).
39. Dzamko, N. et al. AMPK 1 deletion reduces appetite, preventing obesity and hepatic insulin resistance. J. Biol. Chem. 285, 115-122 (2010).
40. Steinberg, G.R. et al. Whole body deletion of AMP-activated protein kinase 2 reduces muscle AMPK activity and exercise capacity. J. Biol. Chem. 285, 37198-37209 (2010).
41. Ussher, J.R. et al. Stimulation of glucose oxidation protects against acute myocardial infarction and reperfusion injury. Cardiovasc. Res. 94, 359-369 (2012).
42. Galic, S. et al. Hematopoietic AMPK 1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesity. J. Clin. Invest. 121, 4903-4915 (2011).
43. Schertzer, J.D. et al. NOD1 activators link innate immunity to insulin resistance. Diabetes 60, 2206-2215 (2011).
44. Steele, R. Influences of glucose loading and of injected insulin on hepatic glucose output. Ann. NY Acad. Sci. 82, 420-430 (1959).
45. Preiss, J. et al. Quantitative measurement of sn-1,2-diacylglycerols present in platelets, hepatocytes, and ras-and sis-transformed normal rat kidney cells. J. Biol. Chem. 261, 8597-8600 (1986). (Pubitemid 17205050)